Alpha Cognition's ZUNVEYL Poised to Revolutionize Alzheimer's Treatment with Unique Oral Therapy

Alpha Cognition Inc. is set to transform Alzheimer's disease treatment with its innovative oral therapy ZUNVEYL, marking a significant advancement in addressing a complex neurological condition that affects millions of Americans.

The newly FDA-approved medication distinguishes itself by targeting mild-to-moderate Alzheimer's disease with a unique prodrug mechanism that dramatically reduces the severe side effects typically associated with existing treatments. With 7 million people affected by Alzheimer's in the United States and 11 million prescriptions written annually, ZUNVEYL addresses a critical unmet medical need.

What sets ZUNVEYL apart is its design to bypass traditional gastrointestinal absorption, substantially mitigating common treatment side effects such as nausea, vomiting, diarrhea, and insomnia. These complications have historically caused 55% of patients to discontinue treatment within a year, representing a significant barrier to effective long-term care.

The company's strategic focus on the long-term care (LTC) market, which represents approximately $2 billion and 36% of Alzheimer's prescriptions, positions ZUNVEYL for potentially rapid market penetration. With 65-70% of LTC patients having access to zero dollar co-pay, the adoption potential appears exceptionally promising.

Alpha Cognition's comprehensive go-to-market strategy includes a 33-person sales team covering over 80% of LTC providers. Notably, 88% of physicians have expressed willingness to prescribe ZUNVEYL, citing its superior safety and efficacy profile.

Beyond its primary application, the company is exploring additional therapeutic opportunities, including a partnership with the Department of Defense to study ZUNVEYL's potential in treating traumatic brain injury, a condition currently lacking FDA-approved treatments.

The company's global expansion strategy is further bolstered by a $44 million licensing deal with China Medical Systems Holdings, indicating international confidence in the treatment's potential.

Led by an experienced management team with over 350 years of collective commercial expertise, including 150 years specifically in the long-term care market, Alpha Cognition appears well-positioned to successfully commercialize ZUNVEYL and potentially transform Alzheimer's disease treatment paradigms.